Brief: Matinas Biopharma Holdings Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia
15/09/2020 12:20
Sept 15 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA HOLDINGS INC - ANNOUNCES POSITIVE END OF
PHASE
2 MEETING WITH FDA FOR MAT9001 IN SEVERE HYPERTRIGLYCERIDEMIA
* MATINAS BIOPHARMA - OFFICIAL MINUTES OF CONFIRMED FDA, CO
ALIGNED ON KEY NEXT STEPS FOR MAT9001'S PHASE 3 DEVELOPMENT
PROGRAM
* MATINAS BIOPHARMA HOLDINGS INC - ON TRACK TO INITIATE ITS
PHASE
3 PROGRAM IN H1 2021
Source text for Eikon: ID:nGNX65SZML
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing